Document Type
Article
Publication Date
1-7-2017
Identifier
PMID: 28061797 PMCID: PMC5219787 DOI: 10.1186/s13045-016-0373-z
Abstract
Osteosarcoma is the most common primary bone cancer affecting children and adolescents worldwide. Despite an incidence of three cases per million annually, it accounts for an inordinate amount of morbidity and mortality. While the use of chemotherapy (cisplatin, doxorubicin, and methotrexate) in the last century initially resulted in marginal improvement in survival over surgery alone, survival has not improved further in the past four decades. Patients with metastatic osteosarcoma have an especially poor prognosis, with only 30% overall survival. Hence, there is a substantial need for new therapies. The inability to control the metastatic progression of this localized cancer stems from a lack of complete knowledge of the biology of osteosarcoma. Consequently, there has been an aggressive undertaking of scientific investigation of various signaling pathways that could be instrumental in understanding the pathogenesis of osteosarcoma. Here, we review these cancer signaling pathways, including Notch, Wnt, Hedgehog, phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT, and JAK/STAT, and their specific role in osteosarcoma. In addition, we highlight numerous natural compounds that have been documented to target these pathways effectively, including curcumin, diallyl trisulfide, resveratrol, apigenin, cyclopamine, and sulforaphane. We elucidate through references that these natural compounds can induce cancer signaling pathway manipulation and possibly facilitate new treatment modalities for osteosarcoma.
Journal Title
J Hematol Oncol
Volume
10
Issue
1
First Page
10
Last Page
10
MeSH Keywords
Adolescent; Biological Products; Child; Humans; Osteosarcoma; Signal Transduction
Keywords
Ezrin; Natural compounds; Osteosarcoma; Signaling pathways
Recommended Citation
Angulo P, Kaushik G, Subramaniam D, et al. Natural compounds targeting major cell signaling pathways: a novel paradigm for osteosarcoma therapy. J Hematol Oncol. 2017;10(1):10. Published 2017 Jan 7. doi:10.1186/s13045-016-0373-z
Included in
Chemical and Pharmacologic Phenomena Commons, Medical Cell Biology Commons, Neoplasms Commons, Oncology Commons, Organic Chemicals Commons, Pediatrics Commons
Comments
Grant support
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Publisher's Link: https://jhoonline.biomedcentral.com/articles/10.1186/s13045-016-0373-z